{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T07:38:41Z","timestamp":1779176321126,"version":"3.51.4"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T00:00:00Z","timestamp":1655337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003819","name":"Natural Science Foundation of Hubei Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003819","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Chimeric antigen receptor T (CAR-T) cell therapy is an attractive strategy for patients with relapsed or refractory hematological malignancies including multiple myeloma (MM). T cells are engineered to attack malignant cells that express tumor-associated antigens and better efficacy could be achieved. However, cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), and hematologic toxicity are still challenges for CAR-T cell therapy. Among them, hematologic toxicity including thrombocytopenia has a longer duration and lasting effect during and after the treatment for some patients. Here, we present 3 cases of hematologic toxicity manifested as refractory thrombocytopenia with platelet autoantibodies positive and plasma thrombopoietin (TPO) concentration elevated after bispecific CAR-T cell therapy in relapsed\/refractory (R\/R) MM patients who were successfully treated with standard therapy of immune thrombocytopenia (ITP). Without clear pathogenesis or guidance on therapy published, our cases provide a reference for the treatment of thrombocytopenia after CAR-T cell therapy and inspire exploration of the underlying pathophysiological mechanisms.<\/jats:p>","DOI":"10.3389\/fimmu.2022.898341","type":"journal-article","created":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T10:24:47Z","timestamp":1655375087000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Case Report: ITP Treatment After CAR-T Cell Therapy in Patients With Multiple Myeloma"],"prefix":"10.3389","volume":"13","author":[{"given":"Mengyi","family":"Du","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linlin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiming","family":"Kou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chenggong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heng","family":"Mei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,6,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30729-6","article-title":"Car T-Cell Product Performance in Haematological Malignancies Before and After Marketing Authorisation","volume":"21","author":"Elsallab","year":"2020","journal-title":"Lancet Oncol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"OF9","DOI":"10.1158\/2159-8290.CD-NB2020-030","article-title":"Treating Mcl With Car T Cells","volume":"10","year":"2020","journal-title":"Cancer Discovery"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01467","article-title":"Long-Term Follow-Up of Anti-Cd19 Chimeric Antigen Receptor T-Cell Therapy","volume":"38","author":"Cappell","year":"2020","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B4","article-title":"Car T-Cell Therapy Against B-Cell Maturation Antigen in Multiple Myeloma","volume":"16","author":"Cohen","year":"2018","journal-title":"Clin Adv Hematol Oncol H&O"},{"key":"B5","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1186\/s13045-020-01001-1","article-title":"Safety and Clinical Efficacy of Bcma Car-T-Cell Therapy in Multiple Myeloma","volume":"13","author":"Roex","year":"2020","journal-title":"J Hematol Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0930-x","article-title":"Development of Car-T Cell Therapies for Multiple Myeloma","volume":"34","author":"Gagelmann","year":"2020","journal-title":"Leukemia"},{"key":"B7","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s13045-019-0813-7","article-title":"Multi-Antigen-Targeted Chimeric Antigen Receptor T Cells for Cancer Therapy","volume":"12","author":"Han","year":"2019","journal-title":"J Hematol Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001159","article-title":"Impact of Cytokine Release Syndrome on Cardiac Function Following Cd19 Car-T Cell Therapy in Children and Young Adults With Hematological Malignancies","volume":"8","author":"Shalabi","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-019-0487-3","article-title":"Early and Late Hematologic Toxicity Following Cd19 Car-T Cells","volume":"54","author":"Fried","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.reth.2020.03.005","article-title":"Idiopathic Thrombocytopenic Purpura Treatment in a Relapsed\/Refractory Multiple Myeloma Patient After Chimeric Antigen Receptor T Cell Therapy","volume":"14","author":"Qiu","year":"2020","journal-title":"Regener Ther"},{"key":"B11","doi-asserted-by":"publisher","first-page":"789","DOI":"10.3390\/jcm10040789","article-title":"Primary Immune Thrombocytopenia: Novel Insights Into Pathophysiology and Disease Management","volume":"10","author":"Singh","year":"2021","journal-title":"J Clin Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15404","article-title":"Detection of Platelet Autoantibodies to Identify Immune Thrombocytopenia: State of the Art","volume":"182","author":"Porcelijn","year":"2018","journal-title":"Br J Haematol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current Concepts in the Diagnosis and Management of Cytokine Release Syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e002721","DOI":"10.1136\/jitc-2021-002721","article-title":"Thrombopoietin Receptor Agonists for Acquired Thrombocytopenia Following Anti-Cd19 Car-T-Cell Therapy: A Case Report","volume":"9","author":"Baur","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B16","doi-asserted-by":"crossref","DOI":"10.1002\/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U","article-title":"A Clinical Staging System for Multiple Myeloma. Correlation of Measured Myeloma Cell Mass With Presenting Clinical Features, Response to Treatment, and Survival","volume":"36","author":"Durie","year":"1975","journal-title":"Cancer"},{"key":"B17","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s40364-020-00190-8","article-title":"Biomarkers in Individualized Management of Chimeric Antigen Receptor T Cell Therapy","volume":"8","author":"Du","year":"2020","journal-title":"biomark Res"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25582","article-title":"Anti-Cd19 Chimeric Antigen Receptor-Modified T-Cell Therapy Bridging to Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed\/Refractory B-Cell Acute Lymphoblastic Leukemia: An Open-Label Pragmatic Clinical Trial","volume":"94","author":"Jiang","year":"2019","journal-title":"Am J Hematol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020010543","article-title":"Car-Hematotox: A Model for Car T-Cell-Related Hematologic Toxicity in Relapsed\/Refractory Large B-Cell Lymphoma","volume":"138","author":"Rejeski","year":"2021","journal-title":"Blood"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.3390\/cancers13071532","article-title":"Autoimmune Complications in Hematologic Neoplasms","volume":"13","author":"Barcellini","year":"2021","journal-title":"Cancers"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-018-3515-2","article-title":"Autoimmune Disease-Associated Non-Hodgkin's Lymphoma-A Large Retrospective Study From China","volume":"98","author":"Hu","year":"2019","journal-title":"Ann Hematol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1111\/jth.12524","article-title":"Association of Autoantibody Specificity and Response to Intravenous Immunoglobulin G Therapy in Immune Thrombocytopenia: A Multicenter Cohort Study","volume":"12","author":"Peng","year":"2014","journal-title":"J Thromb Haemost"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23562","article-title":"Thrombopoietin Levels in Patients With Disorders of Platelet Production: Diagnostic Potential and Utility in Predicting Response to Tpo Receptor Agonists","volume":"88","author":"Makar","year":"2013","journal-title":"Am J Hematol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-11-751719","article-title":"Lack of Detectable Platelet Autoantibodies Is Correlated With Nonresponsiveness to Rituximab Treatment in Itp Patients","volume":"129","author":"Porcelijn","year":"2017","journal-title":"Blood"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2013.09.004","article-title":"Targeting Interleukin-6 in Inflammatory Autoimmune Diseases and Cancers","volume":"141","author":"Yao","year":"2014","journal-title":"Pharmacol Ther"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20190418","article-title":"Biology and Therapeutic Potential of Interleukin-10","volume":"217","author":"Saraiva","year":"2020","journal-title":"J Exp Med"},{"key":"B27","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1111\/cei.12279","article-title":"Alterations in Immune Cell Subsets and Their Cytokine Secretion Profile in Childhood Idiopathic Thrombocytopenic Purpura (Itp)","volume":"176","author":"Talaat","year":"2014","journal-title":"Clin Exp Immunol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1007\/s00277-008-0535-3","article-title":"Profile of Th17 Cytokines (Il-17, Tgf-Beta, Il-6) and Th1 Cytokine (Ifn-Gamma) in Patients With Immune Thrombocytopenic Purpura","volume":"87","author":"Ma","year":"2008","journal-title":"Ann Hematol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"797","DOI":"10.12659\/MSM.884017","article-title":"Immune Thrombocytopenia: Serum Cytokine Levels in Children and Adults","volume":"19","author":"Culi\u0107","year":"2013","journal-title":"Med Sci Monit"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/8825618","article-title":"Lenalidomide-Associated Immune Thrombocytopenia: A Case Report and Review of the Literature","volume":"2020","author":"Forehand Iii","year":"2020","journal-title":"Case Rep Hematol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.898341\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T10:24:52Z","timestamp":1655375092000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.898341\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,16]]},"references-count":30,"alternative-id":["10.3389\/fimmu.2022.898341"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.898341","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,16]]},"article-number":"898341"}}